Narrative Review
Recently published articles about Narrative Review
Narrative Review
Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials
April 29, 2026
The TDIS followed a similar trajectory to other clinician- and patient-reported outcomes measured in tardive dyskinesia clinical trials, and a change of 4 points in total score is considered...
Recent JCP Articles on Narrative Review
Narrative Review
Immune Targeted Therapies for Depression: Antidepressant Effects of Monoclonal Antibodies
June 24, 2024
Immune dysregulation may contribute to treatment resistance in depression. Monoclonal antibodies have shown promise in treating depression when used for inflammatory disorders and may offer new hope for patients...
Recent PCC Articles on Narrative Review
Narrative Review
Management of Sleep Disturbances in Veterans Following Mild TBI
September 12, 2024
The authors developed an evidence- and consensus-based clinical recommendation regarding primary care management of insufficient and disturbed sleep associated with concussion/mild traumatic brain injury in service members and veterans.
Narrative Review
Management of ADHD in Adolescents and Young Adults
August 6, 2024
Drawing on their clinical experiences of implementing evidence-based guidelines and feedback from patients, the authors describe innovative strategies and solutions for improving the management of ADHD in adolescents and...
Featured Narrative Review Research
Letter to the Editor
Peer Support to Prevent Suicide Among Medical Students
May 14, 2026
The authors describe a peer support panel discussion designed to address suicide prevention, allowing medical students to actively participate in addressing critical mental health challenges they face in their...
Narrative Review
Incretin Therapies: A New Tool to Combat Metabolic Consequences of Antipsychotic Use
September 4, 2025
Incretin therapies have emerged as a promising treatment option with potential benefits for mitigating cardiometabolic side effects associated with antipsychotics; however, clinical trials have often excluded psychiatric populations.
Narrative Review
Idiopathic Hypersomnia: Recognition and Management in Psychiatric Practice
June 2, 2025
Idiopathic hypersomnia, characterized by excessive daytime sleepiness (EDS), has an estimated population prevalence up to 1.5%. Psychiatric medications may exacerbate EDS and, conversely, idiopathic hypersomnia treatments may exacerbate psychiatric...